Global Non-melanoma Skin Cancer Market 2014-2018 -





Published: May 2014 | Pages: 119 | Format: PDF

 About Non-melanoma Skin Cancer 

 Non-melanoma skin cancer is one of the most common types of cancer in the world. It develops in the upper layers of the skin, but not in melanocytes. There are two types of non-melanoma skin cancer: BCC, which starts in the basal cells, and SCC, which starts in the squamous cells. BCC usually develops in the areas such as the head and neck, whereas SCC starts in the face, ears, neck, lips, and backs of the hands. These can also grow in wounds or chronic skin sores. Non-melanoma skin cancer is caused by unprotected and excessive exposure to UV radiation. It affects men more than women. It can be cured effectively if it is detected early. Treatment for non-melanoma skin cancer includes surgery, laser therapy, cryotherapy, creams, radiotherapy, chemotherapy, and PDT. 

 TechNavio's analysts forecast the Global Non-melanoma Skin Cancer market to grow at a CAGR of 27.93 percent over the period 2013-2018. 

 Covered in this Report 

 This report covers the present scenario and the growth prospects of the Global Non-melanoma Skin Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the following segments: 

 

  •  Chemotherapy, which includes drugs used in the treatment of SCC, BCC, and actinic keratosis 
  •  Non-invasive Treatments, which include PDT, radiotherapy, cryotherapy, and laser therapy 

 

 TechNavio's report, the Global Non-melanoma Skin Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and, the EMEA and the APAC region; and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. 

 Key Vendors 

 

  •  Elekta AB 
  •  F. Hoffmann-la Roche Ltd. 
  •  iCAD Inc. 
  •  Meda AB 
  •  Valeant Pharmaceuticals Inc. 
  •  Varian Medical Systems Inc. 

 

 Other Prominent Vendors 

 

  •  Aqua Pharmaceuticals LLC 
  •  Almirall SA 
  •  Biofrontera AG 
  •  Boehringer Ingelheim GmbH 
  •  Bristol Myers Squibb Co. 
  •  Cannabis Science Inc. 
  •  Cellceutix Corp. 
  •  Eli Lilly and Co. 
  •  Galderma SA 
  •  GENEXTRA SpA 
  •  IRX Therapeutics Inc. 
  •  LEO Pharma A/S 
  •  Merck & Co. Inc. 
  •  Moberg Pharma AB 
  •  Mylan Pharmaceutical Inc. 
  •  Novartis International AG 
  •  Oncothyreon Inc. 
  •  Sun Pharma Industries Ltd. 

 

 Market Driver 

 

  •  Increasing Incidence of Non-melanoma Skin Cancer 
  •  For a full, detailed list, view our report. 

 

 Market Challenge 

 

  •  Availability of Alternative Treatments 
  •  For a full, detailed list, view our report. 

 

 Market Trend 

 

  •  Emergence of Combination Therapies 
  •  For a full, detailed list, view our report. 

 

 Key Questions Answered in this Report 

 

  •  What will the market size be in 2018 and what will the growth rate be? 
  •  What are the key market trends? 
  •  What is driving this market? 
  •  What are the challenges to market growth? 
  •  Who are the key vendors in this market space? 
  •  What are the market opportunities and threats faced by the key vendors? 
  •  What are the strengths and weaknesses of the key vendors? 

 

**Fiver User License Available for $3,300.

 01. Executive Summary 

 02. List of Abbreviations 

 03. Scope of the Report 

 03.1 Market Overview 

 03.2 Product Offerings 

 04. Market Research Methodology 

 04.1 Market Research Process 

 04.2 Research Methodology 

 05. Introduction 

 06. Market Landscape 

 06.1 Market Overview 

 06.2 Market Size and Forecast 

 06.3 Global Non-melanoma Skin Cancer Drugs Market 

 06.3.1 Market Size and Forecast 

 06.4 Global Actinic Keratosis Drugs Market 

 06.4.1 Market Overview 

 06.4.2 Market Size and Forecast 

 06.5 Top Selling Drugs for the Treatment of BCC, SCC, and Actinic Keratosis 

 06.6 Five Forces Analysis 

 07. Market Segmentation by Type 

 07.1 Global Non-melanoma Skin Cancer Drugs Market by Type 

 07.1.1 BCC 

 07.1.2 SCC 

 07.2 Global BCC Drugs Market 

 07.2.1 Market Size and Forecast 

 07.3 Global SCC Drugs Market 

 07.3.1 Market Size and Forecast 

 08. Pipeline Analysis 

 09. Geographical Segmentation 

 09.1 Global Non-melanoma Skin Cancer Market by Geographical Segmentation 

 10. Buying Criteria 

 11. Market Growth Drivers 

 12. Drivers and their Impact 

 13. Market Challenges 

 14. Impact of Drivers and Challenges 

 15. Market Trends 

 16. Trends and their Impact 

 17. Vendor Landscape 

 17.1 Market Share Analysis 2013 

 17.2 Global Actinic Keratosis Drugs Market 

 17.3 Other Prominent Vendors 

 18. Non-invasive Treatment Market 

 18.1 Global Non-melanoma Skin Cancer Radiotherapy Market 

 18.1.1 Market Size and Forecast 

 18.2 Global Non-melanoma Skin Cancer Cryotherapy Market 

 18.2.1 Market Size and Forecast 

 18.3 Global Non-melanoma Skin Cancer PDT Market 

 18.3.1 Market Size and Forecast 

 18.4 Global Non-melanoma Skin Cancer Laser Therapy Market 

 18.4.1 Market Size and Forecast 

 18.5 Vendor Share 

 18.5.1 Global Non-melanoma Skin Cancer Radiotherapy Equipment Market 

 18.5.2 Global Non-melanoma Skin Cancer Cryotherapy Equipment Market 

 18.5.3 Global Non-melanoma Skin Cancer PDT Equipment Market 

 18.5.4 Global Non-melanoma Skin Cancer Laser Equipment Market 

 19. Key Vendor Analysis 

 19.1 Elekta AB 

 19.1.1 Key Facts 

 19.1.2 Business Description 

 19.1.3 Product Categorization 

 19.1.4 Revenue by Product Offerings 

 19.1.5 Revenue Comparison by Geographical Segmentation 2012 and 2013 

 19.1.6 Revenue Comparison by Geographical Segmentation 

 19.1.7 Business Strategy 

 19.1.8 Key Developments 

 19.1.9 SWOT Analysis 

 19.1.10 Strengths 

 19.1.11 Weaknesses 

 19.1.12 Opportunities 

 19.1.13 Threats 

 19.2 F. Hoffmann-La Roche Ltd. 

 19.2.1 Key Facts 

 19.2.2 Business Description 

 19.2.3 Business Segmentation 

 19.2.4 Revenue by Business Segmentation 

 19.2.5 Geographical Sales Segmentation by Business Segments 

 19.2.6 Business Strategy 

 19.2.7 Key Information 

 19.2.8 SWOT Analysis 

 19.2.9 Strengths 

 19.2.10 Weaknesses 

 19.2.11 Opportunities 

 19.2.12 Threats 

 19.3 iCAD Inc. 

 19.3.1 Key Facts 

 19.3.2 Business Description 

 19.3.3 Business Segmentation 

 19.3.4 Revenue by Business Segmentation 

 19.3.5 Revenue Comparison by Business Segmentation 2012 and 2013 

 19.3.6 Revenue by Geographical Segmentation 

 19.3.7 Business Strategy 

 19.3.8 Key Developments 

 19.3.9 SWOT Analysis 

 19.3.10 Strengths 

 19.3.11 Weaknesses 

 19.3.12 Opportunities 

 19.3.13 Threats 

 19.4 Meda AB 

 19.4.1 Key Facts 

 19.4.2 Business Description 

 19.4.3 Product Segmentation 

 19.4.4 Revenue by Product Segmentation 

 19.4.5 Revenue Comparison by Product Segmentation 2012 and 2013 

 19.4.6 Revenue by Geographical Segmentation 

 19.4.7 Business Strategy 

 19.4.8 Key Developments 

 19.4.9 SWOT Analysis 

 19.4.10 Strengths 

 19.4.11 Weaknesses 

 19.4.12 Opportunities 

 19.4.13 Threats 

 19.5 Valeant Pharmaceuticals International Inc. 

 19.5.1 Key Facts 

 19.5.2 Business Description 

 19.5.3 Business Segmentation 

 19.5.4 Revenue Comparison by Business Segmentation 2011-2013 

 19.5.5 Revenue by Geographical Segmentation 

 19.5.6 Business Strategy 

 19.5.7 Key Developments 

 19.5.8 SWOT Analysis 

 19.5.9 Strengths 

 19.5.10 Weaknesses 

 19.5.11 Opportunities 

 19.5.12 Threats 

 19.6 Varian Medical Systems Inc. 

 19.6.1 Key Facts 

 19.6.2 Business Description 

 19.6.3 Business Segmentation 

 19.6.4 Revenue by Business Segmentation 

 19.6.5 Revenue Comparison by Business Segmentation 2013 and 2012 

 19.6.6 Revenue by Geographical Segmentation 

 19.6.7 Business Strategy 

 19.6.8 Key Developments 

 19.6.9 SWOT Analysis 

 19.6.10 Strengths 

 19.6.11 Weaknesses 

 19.6.12 Opportunities 

 19.6.13 Threats 

 20. Other Reports in this Series 

 

 List of Exhibits: 

 Exhibit 1: Market Research Methodology 

 Exhibit 2: Global Non-melanoma Skin Cancer Market Segmentation by Type 

 Exhibit 3: Global Non-melanoma Skin Cancer Market 2013-2020 (US$ million) 

 Exhibit 4: Global Non-melanoma Skin Cancer Drugs Market 2013-2020 (US$ million) 

 Exhibit 5: Global Actinic Keratosis Drugs Market 2013-2020 (US$ million) 

 Exhibit 6: Global Non-melanoma Skin Cancer Drugs Market Segmentation by Type 

 Exhibit 7: Global Non-melanoma Skin Cancer Drugs Market Segmentation by Type 2013 

 Exhibit 8: Global BCC Drugs Market 2013-2020 (US$ million) 

 Exhibit 9: Global SCC Drugs Market 2013-2020 (US$ million) 

 Exhibit 10: Global Non-melanoma Skin Cancer Market by Geographical Segmentation 2013 

 Exhibit 11: Global Actinic Keratosis Drugs Market by Vendor Segmentation 2013 

 Exhibit 12: Global Non-melanoma Skin Cancer Radiotherapy Market 2013-2020 (US$ million) 

 Exhibit 13: Global Non-melanoma Skin Cancer Cryotherapy Market 2013-2020 (US$ million) 

 Exhibit 14: Global Non-melanoma Skin Cancer PDT Market 2013-2020 (US$ million) 

 Exhibit 15: Global Non-melanoma Skin Cancer Laser Therapy Market 2013-2020 (US$ million) 

 Exhibit 16: Global Non-melanoma Skin Cancer Radiotherapy Equipment Market by Vendor Segmentation 2013 

 Exhibit 17: Global Non-melanoma Skin Cancer Cryotherapy Equipment Market by Vendor Segmentation 2013 

 Exhibit 18: Global Non-melanoma Skin Cancer PDT Equipment Market by Vendor Segmentation 2013 51 

 Exhibit 19: Vendors in Global Non-melanoma Skin Cancer Laser Equipment Market 

 Exhibit 20: Elekta AB: Product Categorization 

 Exhibit 21: Elekta AB: Revenue by Product Offerings 2013 

 Exhibit 22: Elekta AB: Revenue Comparison by Geographical Segmentation 2012 and 2013 (US$ million) 

 Exhibit 23: Elekta AB: Revenue Comparison by Geographical Segmentation 2013 

 Exhibit 24: F. Hoffmann-la Roche Ltd.: Business Segmentation 2013 

 Exhibit 25: F. Hoffmann-la Roche Ltd.: Revenue by Business Segmentation 2012 and 2013 

 Exhibit 26: F. Hoffmann-la Roche Ltd.: Revenue of Pharmaceuticals Division by Geographical Segmentation 2013 

 Exhibit 27: F. Hoffmann-la Roche Ltd.: Revenue of Diagnostics Division by Geographical Segmentation 2013 

 Exhibit 28: iCAD Inc.: Business Segmentation 

 Exhibit 29: iCAD Inc.: Revenue by Business Segmentation 2013 

 Exhibit 30: iCAD Inc.: Revenue Comparison by Business Segmentation 2012 and 2013 (US$ million) 

 Exhibit 31: iCAD Inc.: Revenue by Geographical Segmentation 2013 

 Exhibit 32: Meda AB: Product Segmentation 

 Exhibit 33: Meda AB: Revenue by Product Segmentation 2013 

 Exhibit 34: Meda AB: Revenue Comparison by Product Segmentation 2012 and 2013 (US$ billion) 

 Exhibit 35: Meda AB: Revenue by Geographical Segmentation 2013 

 Exhibit 36: Valeant Pharmaceuticals International Inc.: Business Segmentation 2013 

 Exhibit 37: Valeant Pharmaceuticals International Inc.: Revenue Comparison by Business Segmentation 2011-2013 (US$ million) 

 Exhibit 38: Valeant Pharmaceuticals International Inc.: Revenue by Geographical Segmentation 2013 

 Exhibit 39: Varian Medical Systems Inc.: Business Segmentation 

 Exhibit 40: Varian Medical Systems Inc.: Revenue by Business Segmentation 2013 

 Exhibit 41: Varian Medical Systems Inc.: Revenue Comparison by Business Segmentation (US$ million) 

 Exhibit 42: Varian Medical Systems Inc.: Revenue Segmentation by Geographical Segmentation 2013